Silencing PLSCR1 Curbs Brain Inflammation and Memory Loss in Alzheimer’s Mice by Dampening the NLRP3 Inflammasome

A single molecular switch in the brain’s resident immune cells may hold the key to calming the destructive inflammation that drives Alzheimer’s disease. In a new study published in BMC Neuroscience, researchers report that phospholipid scramblase 1, a protein better known for shuttling lipids across cell membranes, becomes markedly elevated in the brains of Alzheimer’s model mice and appears to fuel the inflammatory cascade that damages memory circuits. When the team silenced this protein, the animals’ cognitive performance improved, their microglia adopted a calmer, more repair-oriented state, and a powerful inflammatory machine inside these immune cells known as the NLRP3 inflammasome fell quiet.

Alzheimer’s disease remains the most common form of dementia worldwide, and while much research has focused on amyloid plaques and tau tangles, a growing body of evidence points to neuroinflammation as a central engine of disease progression. At the heart of this process are microglia, the brain’s native immune sentinels. In healthy tissue, microglia patrol the brain, clear debris, and support neuronal function. In Alzheimer’s disease, however, they become reactive, releasing a storm of pro-inflammatory signaling molecules such as tumor necrosis factor-alpha, interleukin-6, and interleukin-1 beta that can injure the very neurons they are meant to protect. Understanding what tips microglia into this destructive mode has become one of the most urgent questions in neurodegeneration research.

Phospholipid scramblase 1 has previously been implicated in promoting inflammatory responses in other contexts, which prompted the authors, Lixiang Gao of the Department of Neurology at Yantai Affiliated Hospital of Shandong Medical and Pharmaceutical University and Yuejun Lin of the Department of Neurology at Yantaishan Hospital Affiliated to Shandong Medical and Pharmaceutical University, to investigate whether the protein contributes to the pathogenesis of Alzheimer’s disease. Their strategy combined animal and cell-based approaches. In vivo, they used APP/PS1 transgenic mice, a widely used model that develops amyloid pathology and memory deficits, and achieved PLSCR1 knockdown to assess its effects on NLR family pyrin domain containing 3, or NLRP3, inflammasome activation in microglia. In vitro, they turned to BV2 microglial cells stimulated with lipopolysaccharide, a bacterial molecule that reliably provokes inflammatory activation, to dissect the effects of PLSCR1 on cell viability and inflammatory signaling.

The first key observation was that PLSCR1 expression was markedly upregulated in the hippocampus of APP/PS1 mice, the brain region most critical for forming new memories and one of the earliest areas affected in Alzheimer’s disease. The same elevation appeared in LPS-induced BV2 microglial cells, suggesting that PLSCR1 induction is a consistent feature of the inflammatory state that characterizes the disease in both living brain tissue and isolated immune cells. This pattern positioned PLSCR1 not as a passive bystander but as a candidate driver of the neuroinflammatory process, prompting the team to ask what happens when the protein is removed from the equation.

The answer was striking. PLSCR1 knockdown improved cognitive dysfunction in the APP/PS1 mice, indicating that dampening this single protein translated into measurable functional benefits for the animals. Behind that behavioral improvement lay a broad remodeling of the inflammatory environment. When PLSCR1 was silenced, expression of the pro-inflammatory mediators TNF-alpha, iNOS, IL-6, and IL-1 beta went down, while expression of anti-inflammatory and repair-associated markers, including ARG-1, CD206, IL-10, IL-13, and IL-4, went up. In effect, the balance of microglial activity shifted away from a damage-promoting phenotype and toward a restorative one, the kind of polarization that supports tissue healing rather than chronic injury.

The cell culture experiments reinforced this picture and clarified the mechanism. Exposure to lipopolysaccharide promoted microglial activity in the BV2 cells, but PLSCR1 knockdown attenuated that activation and counteracted the LPS-induced shift of microglia toward a pro-inflammatory phenotype. In other words, even when the cells were bombarded with a potent inflammatory trigger, removing PLSCR1 kept them from fully committing to the aggressive state. This suggests that PLSCR1 acts upstream of or in parallel with external inflammatory signals, functioning as a kind of permission factor that allows microglia to escalate their response. Blocking that permission, the data imply, can restrain the escalation itself.

Central to the study’s conclusions is the NLRP3 inflammasome, a multiprotein complex assembled within immune cells that acts as a molecular alarm and munitions factory. When activated, NLRP3 initiates a cascade that processes interleukin-1 beta and related cytokines into their mature, highly inflammatory forms, and its chronic activation has been repeatedly linked to neurodegeneration. The researchers found that PLSCR1 knockdown suppressed NLRP3 inflammasome activation in microglia both in vivo and in vitro, providing a mechanistic thread that connects the protein to the production of interleukin-1 beta and, ultimately, to the cognitive decline observed in the mice. By closing this pathway, PLSCR1 silencing appeared to cut the inflammatory cascade off at a critical junction.

The implications for Alzheimer’s therapy are intriguing, though the authors frame the work as identifying a target rather than delivering a treatment. Current approaches to the disease, including amyloid-targeting antibodies, address upstream pathology but do not directly resolve the neuroinflammatory component that many researchers believe drives ongoing neuronal loss. A strategy that restrains microglial activation through PLSCR1 or the NLRP3 inflammasome could, in principle, complement plaque-directed therapies by protecting the brain’s vulnerable circuits from collateral inflammatory damage. The findings also raise the possibility that PLSCR1 levels could serve as a biomarker of inflammatory activity in the Alzheimer’s brain, helping clinicians track disease state or treatment response.

As with any preclinical study, important steps remain before these results can inform human medicine. The experiments were conducted in a transgenic mouse model and in a microglial cell line, and the complexity of human Alzheimer’s disease, in which inflammation interacts with vascular, metabolic, and genetic factors over decades, may present additional layers of regulation not captured here. Nevertheless, the study delivers a clear and internally consistent message: PLSCR1 functions as a key driver of neuroinflammation and cognitive decline in Alzheimer’s disease, operating through activation of the NLRP3 inflammasome in microglia. By demonstrating that reducing PLSCR1 improves cognition while simultaneously lowering inflammatory cytokines, promoting repair-associated microglial markers, and suppressing inflammasome signaling, Gao and Lin have added a compelling new node to the growing map of Alzheimer’s neuroimmunology, and one that researchers studying inflammasome-targeted therapies will be watching closely.

Subject of Research: The role of PLSCR1 in microglial NLRP3 inflammasome activation and neuroinflammation in Alzheimer's disease

Article Title: PLSCR1 knockdown reduces inflammatory microglial activation in Alzheimer’s disease by inhibiting NLRP3 inflammasome

Article References: Gao, L., & Lin, Y. (2026). PLSCR1 knockdown reduces inflammatory microglial activation in Alzheimer’s disease by inhibiting NLRP3 inflammasome. BMC Neuroscience. https://doi.org/10.1186/s12868-026-01045-y

Image Credits: AI Generated

DOI: 10.1186/s12868-026-01045-y

Keywords: Alzheimer's disease, PLSCR1, microglia, NLRP3 inflammasome, neuroinflammation, cognitive decline, APP/PS1 mice, BV2 cells, interleukin-1 beta, neurodegeneration, knockdown, reduces